(Fargo, ND) Aldevron announced the completion of a 4,500-square-foot expansion of its GMP and GMP-Source™ biological manufacturing facilities in Fargo, North Dakota. The project increases the company’s available production capacity by over 35%. This expansion is in response to increasing demand for Aldevron’s custom plasmid, therapeutic RNA transcript, and enzyme services, and affirms the Company's position as a global leader in contract manufacturing for the biopharmaceutical industry. Aldevron’s products are used in a wide array of gene therapy, gene editing, and immunotherapy programs.
Aldevron’s operations began in a laboratory at North Dakota State University in 1998 and have grown to include sites in Fargo, Madison, Wisconsin, and Freiburg, Germany. The Fargo site currently employs over 100 people and the company expects to increase its headcount to 130 by the end of 2016.
“We are excited to expand our footprint in Fargo and provide our clients with a consistent supply of the highest quality products and services”, said CEO Michael Chambers. “The entire community can be proud of our increased manufacturing capacity, which enable us to serve a rapidly growing number of clients.” Chambers added that the new facility is already being used to make GMP enzymes.
Aldevron began the expansion at its South Fargo campus last December 2015. Nordick Construction served as the general contractor for the project.